Scancell Holdings Plc of the UK has appointed Alan J. Lewis as a non-executive director to help oversee the development of its portfolio of cancer vaccines.
Dr Lewis is currently chief executive of San Diego-based DiaVacs Inc, which is investigating a dendritic cell therapy for patients with Type 1 diabetes. He has previously led and secured deals for the US companies Novocell Inc; Medistem, acquired by Intrexon Inc in 2014 and Signal Pharmaceuticals, acquired by Celgene Corp in 2000. Dr Lewis has a BSc in physiology and biochemistry from Southampton University and a PhD in pharmacology from the University of Wales, both in the UK.
Scancell announced the appointment on 22 August 2016.
Copyright 2016 Evernow Publishing Ltd